Last updated on March 2018

A clinical trial to evaluate treatments using Fumaric acid esters for patients

Brief description of study

The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic treatment for psoriasis.

Fumaric acid esters have been selected as the comparator because it is an established systemic treatment of psoriasis in Germany.

Detailed Study Description

A 24-week, randomised, open-label, active-controlled, parallel group, multi-centre trial with investigator-blinded efficacy assessments

Clinical Study Identifier: NCT03331835

Contact Investigators or Research Sites near you

Start Over

Clinical Disclosure Specialist

Friedrichshafen, Germany
  Connect »